We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
-2.33%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$165M
AUM Growth
-$225M
Cap. Flow
-$200M
Cap. Flow %
-121.14%
Top 10 Hldgs %
89.08%
Holding
21
New
3
Increased
–
Reduced
13
Closed
–
Avg Time Held
4.5 quarters
Top 10 Avg Time Held
4.7 quarters
Top 20 Avg Time Held
4.5 quarters

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$2.63M
2
PDSB icon
PDS Biotechnology
PDSB
+$2.18M
3
CTMX icon
CytomX Therapeutics
CTMX
+$1.19M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$114M
2
RGNX icon
Regenxbio
RGNX
+$20.5M
3
ASND icon
Ascendis Pharma A/S
ASND
+$12.6M
4
AKTX icon
Akari Therapeutics
AKTX
+$6.86M
5
CHRS icon
Coherus Oncology
CHRS
+$6.67M

Sector Composition

Rank Sector Weight
1 Healthcare 69.71%
2 Miscellaneous 30.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HRTX icon
1
Heron Therapeutics
HRTX
$77.1M
$29.3M 17.68%
1,095,734
– –
2013 Q3
9 quarters
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$21.7M 13.09%
311,853
– –
2013 Q2
10 quarters
ANAC
3
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$15.9M 9.61%
140,756
-1,037,718
-88% -$114M
2013 Q2
10 quarters
CHRS icon
4
Coherus Oncology
CHRS
$165M
$14M 8.48%
611,010
-259,259
-30% -$6.67M
2014 Q4
4 quarters
LPCN icon
5
Lipocine
LPCN
$14.2M
$11M 6.64%
49,995
-24,706
-33% -$5.18M
2014 Q2
6 quarters
ADVM icon
6
DELISTED
Adverum Biotechnologies
ADVM
$10.5M 6.35%
110,274
-28,000
-20% -$2.46M
2014 Q3
5 quarters
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
$6.11M 3.69%
500,000
– –
2014 Q1
7 quarters
LRMR icon
8
Larimar Therapeutics
LRMR
$277M
$3.41M 2.06%
45,123
– –
2014 Q2
6 quarters
ARCT icon
9
Arcturus Therapeutics
ARCT
$391M
$3.04M 1.84%
69,214
-145,072
-68% -$6.53M
2015 Q1
3 quarters
AKTX icon
10
Akari Therapeutics
AKTX
$20M
$2.3M 1.39%
198
-462
-70% -$6.86M
2015 Q3
1 quarter
OCRX
11
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.2M 1.33%
703,730
– –
2013 Q4
8 quarters
ORKA icon
12
Oruka Therapeutics
ORKA
$5.44B
$2.15M 1.3%
2,141
-4,995
-70% -$5.66M
2015 Q2
2 quarters
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.96M 1.19%
+60,691
New +$2.63M
2015 Q4
0 quarters
PDSB icon
14
PDS Biotechnology
PDSB
$100M
$1.69M 1.02%
+6,750
New +$2.18M
2015 Q4
0 quarters
ASND icon
15
Ascendis Pharma A/S
ASND
$15.1B
$1.65M 1%
90,000
-721,152
-89% -$12.6M
2015 Q1
3 quarters
CTMX icon
16
CytomX Therapeutics
CTMX
$560M
$1.56M 0.95%
+75,000
New +$1.19M
2015 Q4
0 quarters
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.13M 0.68%
1,875
-4,375
-70% -$2.96M
2015 Q3
1 quarter
RGNX icon
18
Regenxbio
RGNX
$533M
$872K 0.53%
52,500
-1,030,954
-95% -$20.5M
2015 Q3
1 quarter
STML
19
DELISTED
Stemline Therapeutics, Inc.
STML
$855K 0.52%
135,420
-315,980
-70% -$2.56M
2014 Q3
5 quarters

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q4 2015 Portfolio in Review

As of Q4 2015, VHCP Management held 21 positions worth $165M, down 58% from $390M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

VHCP Management withdrew a net $200M in Q4 2015, reducing 13 holdings. Its largest reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $114M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 51% a quarter earlier, followed by Miscellaneous.

Against the trend, VHCP Management opened a new position in Global Blood Therapeutics, Inc. worth $1.96M.

  • VHCP Management's largest Q4 2015 buy was Global Blood Therapeutics, Inc.: 60,691 shares worth $1.96M.
  • VHCP Management's biggest Q4 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $114M.
  • VHCP Management's ten largest holdings make up 89% of its $165M portfolio in Q4 2015.
  • VHCP Management opened 3 new positions and closed 0 in Q4 2015.
  • VHCP Management's portfolio value fell 58% quarter-over-quarter to $165M.

Based on VHCP Management's 13F filing for Q4 2015, filed 12 Feb 2016.